secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2024-02-13T23:59:59+00:00
Accession:  0000950170-24-014191
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel receives FDA Fast Track Designation for CAN-3110 in recurrent high-grade glioma
--------------------------------------------------------------------------------

- FDA granted Fast Track Designation for CAN-3110, an HSV-1 oncolytic viral immunotherapy for recurrent HGG to improve overall survival.
- Phase 1b data published in Nature (Oct 2023) showed median overall survival ~12 months after single injection vs historical <6-9 months.
- Positive HSV-1 serology associated with mOS of 14 months; T-cell repertoire expansion and local/systemic antitumoral response observed.
- Ongoing phase 1b trial evaluating multiple injections of CAN-3110; additional data expected in H2 2024.
- Fast Track designation may accelerate development and regulatory review for this therapy-resistant brain cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024014191/0000950170-24-014191-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024014191/cadl-20240213.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-014191

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer